Patent classifications
C07D419/14
Substituted Bicyclic Heteroaryl Sulfonamide Derivatives for the Treatment of Cancer
The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof; wherein X.sup.1 is CR.sup.7 or N, X.sup.2 is CR.sup.8 or N, X.sup.3 is CR.sup.9 or N and wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are as defined in the claims, as well as methods of using the compounds for the treatment of neoplastic diseases such as cancer.
Substituted Bicyclic Heteroaryl Sulfonamide Derivatives for the Treatment of Cancer
The invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof; wherein X.sup.1 is CR.sup.7 or N, X.sup.2 is CR.sup.8 or N, X.sup.3 is CR.sup.9 or N and wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8 and R.sup.9 are as defined in the claims, as well as methods of using the compounds for the treatment of neoplastic diseases such as cancer.
DYNAMIN ACTIVATORS
The present disclosure provides compounds of Formula I, a free base form thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical compositions comprising the same, and methods of treating medical disorders using the same.
DYNAMIN ACTIVATORS
The present disclosure provides compounds of Formula I, a free base form thereof, a pharmaceutically acceptable salt thereof, a pharmaceutical compositions comprising the same, and methods of treating medical disorders using the same.
KIF18A INHIBITORS
Compounds of formula (I):
##STR00001##
as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.
KIF18A INHIBITORS
Compounds of formula (I):
##STR00001##
as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A.